Myopia is advancing at near-epidemic rates in East Asia, with children increasingly diagnosed before age ten — and conventional single-vision spectacles do little to slow its biological progression. A home-deployable intervention that parents can administer in 15 minutes a day would represent a meaningful shift in how families manage this risk, making these results worth careful attention.
This randomized clinical trial, published in JAMA Ophthalmology and conducted at a single center in Guangzhou, enrolled 120 myopic children aged 6 to 12, randomizing them equally to either a head-mounted virtual reality digital defocus vision training (DDVT) system plus standard single-vision spectacles, or spectacles alone. Children in the DDVT arm used the device for 15 minutes daily at home under parental supervision following an initial clinical orientation session. Over the 6-month follow-up period, the trial tracked axial length (AL) — the gold-standard structural marker of myopia progression — as its primary endpoint, alongside spherical equivalent refraction (SER) as a secondary measure. Completion rates were high, at 95% in the DDVT group and 98% in controls, indicating strong real-world feasibility.
The defocus mechanism underlying this approach mirrors the rationale behind orthokeratology and multifocal contact lenses: imposing peripheral myopic defocus signals that theoretically inhibit axial elongation of the eye. What distinguishes this VR system is its potential for standardized, scalable home delivery — a significant logistical advantage over clinic-dependent modalities. However, several limitations temper enthusiasm. The trial spans only six months, insufficient to establish whether axial length benefits compound or attenuate over the multi-year arc of childhood myopia development. The single-center Chinese cohort limits generalizability to other ethnic populations and clinical environments. Additionally, without a sham-device control arm, placebo and behavioral effects cannot be fully disentangled. This trial is best characterized as confirmatory of biological plausibility, with larger, longer multicenter replication needed before clinical integration.